GLP-1s approved for Type 2 diabetes, including Ozempic, Trulicity and Rybelsus, have faced regulatory scrutiny for a range of side effects such as hair loss, aspiration and suicidal thoughts. A potential connection between GLP-1s and pancreatic cancer, though, was suggested to be unfounded in an Israel-based study of more than 500,000 adult patients.
Between 2009 — when GLP-1s became available in Israel — and 2017, the hazard risk for developing pancreatic cancer was similar among diabetes patients who took insulin compared to GLP-1 users. The risk rate for GLP-1s was 0.52, and insulin’s risk rate was 0.75, according to the study.
About 33,000 patients took a GLP-1 and 106,000 used basal insulin. Of the 543,595 patient records part of the study, 1,665, or 0.31%, of the records indicated a pancreatic cancer diagnosis.
The researchers concluded the safety risk was not supported, but said monitoring for pancreatic cancer risk beyond seven years is still required.
The results were published Jan. 4 in JAMA.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.